Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769703 | 0.89 | JAK3 (0.47) | SYKPRKCQIGF1RMAOBGRM5 | |
| SCHEMBL15770163 | 0.87 | SYK (0.46) | SYKPRKCQIGF1RMAOBGRM5 | |
| SCHEMBL15769283 | 0.87 | SYK (0.58) | SYKPRKCQIGF1RMAOBGRM5 | |
| SCHEMBL20752178 | 0.87 | ABCG2 (0.44) | SYKPRKCQIGF1RMAOBGRM5 | |
| SCHEMBL15770254 | 0.87 | ABCG2 (0.44) | SYKPRKCQIGF1RMAOBGRM5 | |
| SCHEMBL20752214 | 0.86 | PRKCQ (0.38) | SYKPRKCQIGF1RCDK1PTK2 | |
| SCHEMBL15769863 | 0.86 | PRKCQ (0.38) | SYKPRKCQIGF1RCDK1PTK2 | |
| SCHEMBL15770092 | 0.86 | TNK2 (0.38) | PRKCQIGF1RCDK1PTK2JAK3 | |
| SCHEMBL15769386 | 0.85 | CHEK1 (0.50) | SYKPRKCQPTK2 | |
| SCHEMBL15769442 | 0.81 | EPHB4 (0.44) | SYKIGF1RMAOBGRM5CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | claimed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | claimed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2928891-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913843-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2015-10-29 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062068-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163022-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | SYK 612/4885PRKCQ 5/4885IGF1R 2703/4885 |
| US-20150306100-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | SYK 612/4885PRKCQ 5/4885IGF1R 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.